• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

    12.19 -0.30 (-2.40%)
    Streaming Delayed Price Updated: 11:07 AM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13,289
    Open 12.29
    Bid (Size) 12.19 (200)
    Ask (Size) 12.36 (100)
    Prev. Close 12.49
    Today's Range 11.83 - 12.50
    52wk Range 8.720 - 21.40
    Shares Outstanding 64,532,091
    Dividend Yield 3.94%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma to Present at March Investor Conferences
    From Crescent Biopharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +10.0%
    +10.0%
    1 Month
    +3.7%
    +3.7%
    3 Month
    -19.2%
    -19.2%
    6 Month
    -14.5%
    -14.5%
    1 Year
    -22.8%
    -22.8%

    More News

    Read More
    News headline image
    Crescent Biopharma Announces Grants of Inducement Awards
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Announces Grants of Inducement Awards
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Announces Grants of Inducement Awards
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today ↗
    Via Stocktwits
    News headline image
    Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
    From Crescent Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
    From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Announces Grants of Inducement Awards
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    Crescent Biopharma to Present at November Investor Conferences
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    Crescent Biopharma to Present at September Investor Conferences
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga
    News headline image
    This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗
    Via Benzinga
    News headline image
    Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
    From Crescent Biopharma
    Via GlobeNewswire
    News headline image
    Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Crescent Biopharma, Inc. - Common Stock publicly traded?
    Yes, Crescent Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Crescent Biopharma, Inc. - Common Stock trade on?
    Crescent Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Crescent Biopharma, Inc. - Common Stock?
    The ticker symbol for Crescent Biopharma, Inc. - Common Stock is CBIO on the Nasdaq Stock Market
    What is the current price of Crescent Biopharma, Inc. - Common Stock?
    The current price of Crescent Biopharma, Inc. - Common Stock is 12.19
    When was Crescent Biopharma, Inc. - Common Stock last traded?
    The last trade of Crescent Biopharma, Inc. - Common Stock was at 02/26/26 11:07 AM ET
    What is the market capitalization of Crescent Biopharma, Inc. - Common Stock?
    The market capitalization of Crescent Biopharma, Inc. - Common Stock is 786.65M
    How many shares of Crescent Biopharma, Inc. - Common Stock are outstanding?
    Crescent Biopharma, Inc. - Common Stock has 787M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.